Abstract Library

#1744 Predictors of Survival in Patients with Small Intestinal Neuroendocrine Tumours (SINETs) Associated with Mesenteric Desmoplasia

Introduction: SINETs represent 30-50% of small bowel neoplasms with a rising incidence and can be associated with mesenteric fibrosis (MF)

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Laskaratos F, Diamantopoulos L, Walker M, Khalifa M, Walton H,

Keywords: SINETs,

#1135 The Role of External Beam Radiotherapy in the Management of Advanced Neuroendocrine Tumors

Introduction: Palliative external beam radiotherapy (EBRT) is routinely used to control symptoms and disease progression in metastatic malignancies, but there is limited data in metastatic neuroendocrine tumours (NET).

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Yalchin M, Tharmalingam H, Owen C, Walker M, Caplin M,

Keywords: EBRT, NET,

#130 Lanreotide Autogel for malignant carcinoid syndrome: an 8-year experience

Introduction: Somatostatin analogues provide symptomatic relief in carcinoid syndrome and recently have been shown to inhibit tumor growth in metastatic gastroenteropancreatic neuroendocrine tumors (NETs). Lanreotide compounds are reported to have similar efficacy to Octreotide compounds. There is limited long-term data available on Lanreoitde Autogel.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Khan M, Aldridge R, Walker R, Toumpanakis C, Caplin M,

Keywords: Lanreotide autogel, carcinoid syndrome, neuroendocrine tumor, somatostatin analogue ,